Neogenomics Inc（NEO）财务数据NEONeogenomics Inc

NeoGenomics, Inc. (NEO) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Clinical Services-Client direct billing, accounting for 68.4% of total sales, equivalent to $137.96M. Other significant revenue streams include Clinical Services-Commercial Insurance and Clinical Services-Medicare and Medicaid. Understanding this composition is critical for investors evaluating how NEO navigates market cycles within the Healthcare Facilities & Services industry.

Evaluating the bottom line, NeoGenomics, Inc. maintains a gross margin of 45.56%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -5.10%, while the net margin is 1.11%. These profitability ratios, combined with a Return on Equity (ROE) of -6.33%, provide a clear picture of how effectively NEO converts its operational activities into shareholder value.

In the context of the broader market, NEO competes directly with industry leaders such as ADUS and MD. With a market capitalization of $2.12B, it holds a significant position in the sector. When comparing efficiency, NEO's gross margin of 45.56% stands against ADUS's 31.12% and MD's 100.00%. Such benchmarking helps identify whether NeoGenomics, Inc. is trading at a premium or discount relative to its financial performance.

Neogenomics has shown some positive revenue growth, with Q2 2026 revenue at $201.66 million and a gross margin of 45.56%. However, it reported a net income of $2.24 million in Q2 2026, indicating a turnaround from previous losses.